Evidence map›Paper›PMID 41957523›Full record

ArticleCancer gene therapy2026

Deciphering the role of SIRT6 in suppressing the AMPK-mTOR-TFEB axis: regulation of autophagy activation in HCC.

Cong Shan Li, Hua Jin, Ruoyu Meng, Seung-Woo Baek, Seong-Hun Kim, Ok Hee Chai, Byung Hyun Park, Ju-Seog Lee, Na Ri Lee, Soo Mi Kim

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cong Shan Li *Department of Physiology, Institute for Medical Sciences, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Hua Jin *Department of Physiology, Institute for Medical Sciences, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Ruoyu Meng *Department of Physiology, Institute for Medical Sciences, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Seung-Woo BaekGenomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.
Seong-Hun KimDepartment of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea.
Ok Hee ChaiDepartment of Anatomy, Institute for Medical Sciences, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Byung Hyun ParkGraduate School of Medical Science and Engineering, Korean Advanced Institute of Science and Technology, Daejon, Republic of Korea.
Ju-Seog LeeDepartment of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Na Ri LeeDepartment of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea. nariflower@jbnu.ac.kr.
Soo Mi KimDepartment of Physiology, Institute for Medical Sciences, Jeonbuk National University Medical School, Jeonju, Republic of Korea. soomikim@jbnu.ac.kr.ORCID http://orcid.org/0000-0002-6784-1459

Funding

The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular CarcinomaP50CA217674 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BERETTA, LAURA, KASEB, AHMED · 2019 to 2023
$11.3M
National Research Foundation of Korea (NRF) 2017R1A5A2015061National Research Foundation of Korea (NRF) 2021R1A2C2013505NCI NIH HHS P50 CA217674
6 · The paper itself

Abstract

Sirtuin 6 (SIRT6), belong to the NAD-dependent class III protein deacetylase family, is implicated in cancer development through a multifaceted role. While it has been identified with both tumor-suppressive and tumor-promoting roles in Hepatocellular carcinoma (HCC), there remains considerable debate regarding its exact function. The specific molecular mechanisms driving its tumor-suppressive effects in HCC remains poorly understood. In this study, we mechanistically identified a novel pathway involving AMP-activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), and transcription factor EB (TFEB): upregulation of SIRT6 enhances AMPK activity and suppresses mTOR activation, leading to TFEB nuclear translocation and the subsequent induction of autophagy. Importantly, our study provides the first evidence that SIRT6 induces the translocation of TFEB into the nucleus, facilitating autophagy. Intriguingly, SIRT6 silencing counteracted the effects of mTOR inhibitors on TFEB and autophagy, suggesting that SIRT6 probably activates lysosome function via an AMPK-mTOR-TFEB axis in HCC. Our in vivo experiments bolster our findings, demonstrating that SIRT6 effectively suppressed HCC tumor growth and metastasis. Overall, our research provides compelling evidence that SIRT6 functions as a tumor suppressor in HCC, offering a valuable therapeutic mechanism for treating HCC and paving the way for a promising avenue in future HCC treatment. Schematic illustration of SIRT6's role in hepatocellular carcinoma. Proposing a model to elucidate the regulatory mechanism of SIRT6-AMPK-mTOR-TFEB signaling axis in orchestrating autophagy activation within hepatocellular carcinoma. Phosphorylation of AMPK by SIRT6 leads to the inhibition of mTOR and its downstream targets. This modulation influences TFEB, promoting its translocation into the nucleus and triggering autophagy activation. This intricate cascade is marked by a significant increase in substrate degradation and the formation of autophagic bilayers, ultimately culminating in the suppression of cell proliferation and the augmentation of cell death.

Indexed as

AMP-Activated Protein KinasesAutophagyBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCarcinoma, HepatocellularLiver NeoplasmsSirtuinsTOR Serine-Threonine KinasesAnimalsCell Line, TumorHumansMiceSignal TransductionAMP-Activated Protein KinasesBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsMTOR protein, humanSIRT6 protein, humanSirtuinsTFEB protein, humanTOR Serine-Threonine Kinases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.